The use of metformin for polycystic ovary syndrome
Abstract
Recently, there is strong evidence that insulin resistance and additive hyperinsulinemia are unique features of the polycystic ovary syndrome (PCOS). Additional studies evaluating the effect of agents affecting hyperinsulinemia are no doubt to be required before making official recommendations on their use in clinical practice. The paper presents data of 12-week metformin therapy in 65 females with PCOS, by analyzing the results of studies of insulinemia and glycemia during oral glucose tolerance tests (OGTT) performed prior to and following the therapy. Insulin resistance and sensitivity, p-cell functions, and a secretory response of insulin to glucose stimulation were evaluated by using mathematical models and by calculating surrogate OGTT indices validated with the reference clamp test. Metformin was found to exert a positive effect on metabolic disorders in females with PCOS via increased insulin sensitivity and a decreased integral secretory response on insulin to oral glucose stimulation, by creating conditions for an adequate response to the stimulus as better insulin-mediated glucose uptake with decreased compensatory hyperinsulinemia. Recovery of adequacy of a secretory response to glucose stimulation promotes a reduction in additive hyperinsulinemia only in PCOSfemales with p-cell dysfunction caused by a predominance of decreased peripheral insulin sensitivity, rather than secretory defect.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.